BioAge Labs, Inc. (BIOA)
NASDAQ: BIOA · Real-Time Price · USD
14.95
-0.46 (-2.99%)
Jan 7, 2026, 2:07 PM EST - Market open
BioAge Labs Employees
As of December 31, 2024, BioAge Labs had 64 total employees, including 62 full-time and 2 part-time employees. The number of employees increased by 8 or 14.29% compared to the previous year.
Employees
64
Change (1Y)
8
Growth (1Y)
14.29%
Revenue / Employee
$92,453
Profits / Employee
-$1,184,234
Market Cap
536.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64 | 8 | 14.29% |
| Dec 31, 2023 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BIOA News
- 4 weeks ago - BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor - GlobeNewsWire
- 6 weeks ago - BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - BioAge Labs to Present at Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 4 months ago - HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor - PRNewsWire
- 4 months ago - BioAge Labs to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor - GlobeNewsWire
- 5 months ago - BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 months ago - BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions - GlobeNewsWire